Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Net Margin (2019 - 2025)

Cyclerion Therapeutics has reported Net Margin over the past 5 years, most recently at 114.97% for Q3 2025.

  • Quarterly results put Net Margin at 114.97% for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was 144.83% (changed N/A YoY), and the annual figure for FY2022 was 8697.64%, down 729747.0%.
  • Net Margin for Q3 2025 was 114.97% at Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
  • Over the last five years, Net Margin for CYCN hit a ceiling of 114.97% in Q3 2025 and a floor of 21604.84% in Q1 2021.
  • Median Net Margin over the past 3 years was 1826.16% (2022), compared with a mean of 4222.73%.
  • Biggest five-year swings in Net Margin: plummeted -1960997bps in 2021 and later soared 1977868bps in 2022.
  • Cyclerion Therapeutics' Net Margin stood at 2690.06% in 2021, then plummeted by -63bps to 4389.87% in 2022, then skyrocketed by 97bps to 114.97% in 2025.
  • The last three reported values for Net Margin were 114.97% (Q3 2025), 1797.85% (Q2 2025), and 1798.77% (Q1 2025) per Business Quant data.